Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994.
To determine the feasibility of a vaccination strategy that would reduce the risk of vaccine-associated paralysis while retaining a barrier against the spread of wild poliovirus, a 2-year project was undertaken using enhanced-potency inactivated poliovirus vaccine (IPV) administered at 2 and 3 months of age followed by doses of both IPV and oral poliovirus vaccine (OPV) administered at 4 and 9 months of age. Vaccination coverage by 12 months of age with three or more doses of IPV and two doses of OPV among 16,566 infants eligible for vaccination was > 95% and > 80%, respectively. Among 51 children from whom blood samples were obtained 45 days after their third dose of IPV and first dose of OPV, 100% had serum neutralizing antibodies (reciprocal titer > or = 10) to all three poliovirus types. No cases of paralytic poliomyelitis due to either wild or vaccine-related strains were reported. The project demonstrated the feasibility, safety, and high immunogenicity of sequential use of IPV followed by OPV in Romania.
Ion-Nedelcu
N
N
Expanded Programme on Immunization, Ministry of Health, National Laboratory for Control of Sera and Vaccines, and Cantacuzino Institute, Bucharest, Romania.
Strebel
P M
PM
Toma
F
F
Biberi-Moroeanu
S
S
Combiescu
M
M
Persu
A
A
Aubert-Combiescu
A
A
Plotkin
S A
SA
Sutter
R W
RW
D000914:Antibodies, Viral / Q000302:isolation & purification; D001500:BCG Vaccine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D017589:Immunization Programs / Q000458:organization & administration; D007115:Immunization Schedule; D007223:Infant; D011051:Poliomyelitis / Q000517:prevention & control*; D017955:Poliovirus / Q000276:immunology / Q000302:isolation & purification; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage* / Q000276:immunology; D012383:Romania
D000914:Antibodies, Viral; D001500:BCG Vaccine; D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral